Merck Q2 2026: Revenue Beats, Guidance Raised, but GAAP Loss on Terns Charge; Keytruda and Winrevair Drive Growth

summarizeSummary

Merck's Q2 2026 revenue of $16.6 billion beat expectations and full-year guidance was raised. A GAAP loss from acquisition accounting masks strong underlying performance led by Keytruda and Winrevair. The IRS dispute and upcoming generic headwinds are key risks.

check_boxKey Events · Earnings and Guidance · MRK

• Q2 Revenue Beats, Guidance Raised

  Revenue of $16.6 billion grew 5% year-over-year, driven by oncology and cardiometabolic products. Full-year 2026 sales guidance was raised, signaling confidence in the growth trajectory.

• GAAP Loss Masks Strong Operations

  The $1.335 billion GAAP net loss ($0.54 per share) was entirely due to a $5.7 billion non-cash R&D charge from the Terns acquisition. Excluding this and other items, non-GAAP EPS was a loss of $0.13, reflecting heavy investment but solid underlying profitability.

• Keytruda and Winrevair Power Growth

  Keytruda/Keytruda Qlex combined sales reached $8.4 billion (+5%), while Winrevair sales surged 75% to $588 million. Welireg also grew 67% to $271 million, demonstrating pipeline momentum.

• IRS Dispute Over $1.3 Billion in Taxes

  The IRS proposed adjustments to Merck's 2017-2018 transition tax, seeking an additional $1.3 billion plus $260 million in penalties. Merck is contesting, but an adverse outcome could be material.

auto_awesomeAnalysis · MRK · Life Sciences

A strong operational quarter pushed revenue to $16.6 billion, up 5%, and prompted a raise in the full-year sales outlook. The reported GAAP net loss of $1.335 billion stems entirely from a $5.7 billion non-cash R&D charge tied to the Terns acquisition—an accounting item that obscures underlying profitability. Combined Keytruda/Keytruda Qlex sales grew 5% to $8.4 billion, while Winrevair continued its rapid launch trajectory, surging 75% to $588 million. The balance sheet reflects $14.6 billion in acquisition spending, with cash and investments falling to $8.4 billion. A material contingent liability looms from the IRS dispute over $1.3 billion in proposed transition tax adjustments. Future revenue will face pressure from the loss of exclusivity for Januvia/Janumet and Bridion, but the pipeline is delivering—Lipfendra and multiple Keytruda label expansions were approved. This filing confirms the company is successfully navigating the post-Keytruda LOE transition, though the IRS matter and generic erosion warrant close attention.